Table 2 Relationships between clinicopathological characteristics and pathological response evaluated by Mandard-TRG system
Characteristics | Total cases (n = 192), no. (%) | Mandard-TRG | P value | ||||
|---|---|---|---|---|---|---|---|
1 (n = 11), no. (%) | 2 (n = 23), no. (%) | 3 (n = 40), no. (%) | 4 (n = 78), no. (%) | 5 (n = 40), no. (%) | |||
Gender | Â | Â | Â | Â | Â | Â | 0.039 |
 Male | 139 (72.4) | 10 (7.2) | 20 (14.4) | 29 (20.9) | 48 (34.5) | 32 (23) |  |
 Female | 53 (27.6) | 1 (1.9) | 3 (5.7) | 11 (20.8) | 30 (56.6) | 8 (15.1) |  |
Age | Â | Â | Â | Â | Â | Â | 0.867 |
 < 55y | 89 (46.4) | 6 (6.7) | 10 (11.2) | 17 (19.1) | 39 (43.8) | 17 (19.1) |  |
 ≥ 55y | 103 (53.6) | 5 (4.9) | 13 (12.6) | 23 (22.3) | 39 (37.9) | 23 (22.3) |  |
Location | Â | Â | Â | Â | Â | Â | 0.351 |
 Esophagogastric junction | 44 (22.9) | 1 (2.3) | 4 (9.1) | 8 (18.2) | 20 (45.5) | 11 (25) |  |
 Proximal gastric | 71 (37) | 7 (9.9) | 8 (11.3) | 15 (21.1) | 23 (32.4) | 18 (25.4) |  |
 Distal gastric | 77 (40.1) | 3 (3.9) | 11 (14.3) | 17 (22.1) | 35 (45.5) | 11 (14.3) |  |
Maximal diameter of tumor bed | Â | Â | Â | Â | Â | Â | 0.004 |
 < 4.5 cm | 108 (56.2) | 9 (8.3) | 20 (18.5) | 20 (18.5) | 44 (40.7) | 15 (13.9) |  |
 4.5–8 cm | 64 (33.3) | 1 (1.6) | 3 (4.7) | 17 (26.6) | 27 (42.2) | 16 (25) |  |
 > 8 cm | 20 (10.4) | 1 (5) | 0 (0) | 3 (15) | 7 (35) | 9 (45) |  |
Histological differentiation | Â | Â | Â | Â | Â | Â | 0.003 |
 Well-moderate | 45 (23.4) | 4 (8.9) | 12 (26.7) | 9 (20) | 16 (35.6) | 4 (8.9) |  |
 Poor | 147 (76.6) | 7 (4.8) | 11 (7.5) | 31 (21.1) | 62 (42.2) | 36 (24.5) |  |
Laurén classification |  |  |  |  |  |  | 0.240 |
 Intestinal | 77 (40.1) | 4 (5.2) | 14 (18.2) | 14 (19.2) | 28 (36.4) | 15 (19.5) |  |
 Diffuse | 73 (38) | 7 (9.6) | 5 (6.8) | 10 (23.8) | 33 (45.2) | 14 (19.2) |  |
 Mixed | 42 (21.9) | 0 (0) | 4 (9.5) | 15 (35.7) | 17 (40.5) | 11 (26.2) |  |
LVI | Â | Â | Â | Â | Â | Â | <0.001 |
 Negative | 94 (49) | 11 (11.7) | 19 (20.2) | 28 (29.8) | 26 (27.7) | 10 (10.6) |  |
 Positive | 98 (51) | 0 (0) | 4 (4.1) | 12 (12.2) | 52 (53.1) | 30 (30.6) |  |
PNI | Â | Â | Â | Â | Â | Â | <0.001 |
 Negative | 76 (39.6) | 11 (14.5) | 22 (28.9) | 13 (17.1) | 23 (30.3) | 7 (9.2) |  |
 Positive | 116 (60.4) | 0 (0) | 1 (0.9) | 27 (23.3) | 55 (47.4) | 33 (28.4) |  |
AJCC ypT category | Â | Â | Â | Â | Â | Â | <0.001 |
 0 | 11 (5.7) | 11 (100) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |  |
 1 | 20 (10.4) | 0 (0) | 12 (60) | 5 (25) | 3 (15) | 0 (0) |  |
 2 | 23 (12) | 0 (0) | 5 (21.7) | 6 (26.1) | 12 (52.2) | 0 (0) |  |
 3 | 57 (29.7) | 0 (0) | 5 (8.8) | 18 (31.6) | 25 (43.9) | 9 (15.8) |  |
 4 | 81 (42.2) | 0 (0) | 1 (1.2) | 11 (13.6) | 38 (46.9) | 31 (38.3) |  |
AJCC ypN category | Â | Â | Â | Â | Â | Â | <0.001 |
 0 | 55 (28.6) | 9 (16.4) | 13 (23.6) | 17 (30.9) | 10 (18.2) | 6 (10.9) |  |
 1 | 36 (18.8) | 0 (0) | 6 (16.7) | 7 (19.4) | 16 (44.4) | 7 (19.4) |  |
 2 | 50 (26) | 0 (0) | 3 (6) | 10 (20) | 32 (64) | 5 (10) |  |
 3 | 51 (26.6) | 2 (3.9) | 1 (2) | 6 (11.8) | 20 (39.2) | 22 (43.1) |  |
AJCC stage | Â | Â | Â | Â | Â | Â | <0.001 |
 0 | 9 (4.7) | 9 (100) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |  |
 1 | 24 (12.5) | 0 (0) | 14 (58.3) | 7 (29.2) | 2 (8.3) | 1 (4.2) |  |
 2 | 53 (27.6) | 2 (3.8) | 6 (11.3) | 14 (26.4) | 21 (39.6) | 10 (18.9) |  |
 3 | 106 (55.2) | 0 (0) | 3 (2.8) | 19 (17.9) | 55 (51.9) | 29 (27.4) |  |
R0 resection | Â | Â | Â | Â | Â | Â | 0.185 |
 Yes | 159 (82.8) | 11 (6.9) | 20 (12.6) | 35 (22) | 64 (40.3) | 29 (18.2) |  |
 No | 33 (17.2) | 0 (0) | 3 (9.1) | 5 (15.2) | 14 (42.4) | 11 (33.3) |  |
Adjuvant chemotherapy | Â | Â | Â | Â | Â | Â | 0.766 |
 Not received | 59 (30.7) | 3 (5.1) | 6 (10.2) | 10 (16.9) | 25 (42.4) | 15 (25.4) |  |
 Received | 133 (69.3) | 8 (6) | 17 (12.8) | 30 (22.6) | 53 (39.8) | 25 (18.8) |  |